1. Introduction {#sec0005}
===============

The incidence of malignant melanoma continues to increase dramatically worldwide, at an overall rate of about 30% in the last 10 years [@bib0005]. In 2014, an estimated 76,100 new cases will be diagnosed and about 9710 patients will die of melanoma in the United States [@bib0005].

Melanoma is increasing in men more rapidly than any other malignancy, and in women more rapidly than any other malignancy except lung cancer (respectively 33% for men and 23% for women) [@bib0005]. In Europe, the incidence varies in different areas, with higher rates in the countries of Northern Europe (12--20 per 100,000 per year) than in the Mediterranean area (3--5 per 100,000 per year) [@bib0010].

Choroidal melanoma is the most common primary intraocular malignant tumour and the second most common type of primary malignant melanoma in the body [@bib0015]. Biologically, cutaneous and ocular melanoma may be considered different, in terms of both metastatic diffusion and metastatic latency [@bib0020]. The principal target organ for metastasis of the ocular melanoma is the liver [@bib0020].

In contrast, cutaneous melanoma spreads primarily to lymph nodes and soft tissues with only a lower incidence of hepatic diffusion (14--20%) [@bib0025]. This distinctive behaviour is also sustained by a different metastatic latency [@bib0020].

We report a case of metastatic choroidal melanoma after twenty years from surgical removal.

2. Presentation of case {#sec0010}
=======================

A 60 year-old male who had undergone left ocular enucleation for choroid melanoma 20 years ago was referred to our department with a three months history of diffuse abdominal pain, fever, weight loss (\> 10 kg) and massive ascites. The histopathological examination of the enucleated left eye showed a mixed-cell-type choroidal melanoma without intrascleral or vascular involvement. The size of the melanoma was 10 mm in thickness and 13 mm in diameter. Since then, the patient had been followed up regularly by an ophthalmologist. The last follow-up at 15 years after eye enucleation was negative for recurrence or metastatic diffusion. At the admission, laboratory tests were normal, except for increase CA-125 marker. Abdominal ultrasonography (US) and total body computed tomography (CT) scan were performed and revealed diffuse liver metastases in both lobes with a tendency to confluence, a large mass involving the gallbladder, associated with peritoneal carcinosis, bilateral adrenal metastases and a large mass in the left kidney (5 cm of diameter) compatible with another secondary localization ([Figs. 1--3](#fig0005 fig0010 fig0015){ref-type="fig"} ). EGDS and colonoscopy were performed in order to exclude other primitive malignant cancers. An ultrasound guided fine needle agobiopsy (FNA) of liver lesions was performed and the pathological findings led to the diagnosis of liver metastasis from choroidal melanoma (S-100 protein, vimentin, HMB-45 and Melan A antibodies positive). Percutaneous evacuative paracentesis was also performed and the cytology confirmed the diagnosis. A protocol of systemic chemotherapy was started but the patient died a few weeks later for hepatic failure.

3. Discussion {#sec0015}
=============

Visceral metastases represent an advanced stage of melanoma and patients that develop metastatic disease continue to have a poor prognosis with a 5-year survival of under 10% [@bib0005].

Liver metastases are usually associated with even worse outcomes, with a median survival of few months [@bib0030]. Choroidal melanoma is the second most common type of primary malignant melanoma in the body and the liver is the principal target organ for metastases [@bib0015].

Among patients that developing metastases, liver metastases can be found in about 90% of the cases and often as a first and only metastatic site in approximately 40% of patients [@bib0015].

Metastatic melanoma to the gall bladder is extremely rare and is associated with a very poor prognosis [@bib0035; @bib0040], delayed metastases to brain, pancreas, adrenal glands and ovaries have also been reported [@bib0045; @bib0050; @bib0055; @bib0060; @bib0065; @bib0070].

The correct treatment of hepatic metastases from ocular and cutaneous melanoma is still object of debate. The recent development of novel agents have demonstrated better efficacy than traditional chemotherapy. Ipilimumab, a monoclonal antibody directed to the immune checkpoint receptor termed "cytotoxic T lymphocyte antigen-4 (CTLA-4)" has been shown to improve overall survival in patients with metastatic melanoma; similarly vemurafenib (a selective B-Raf inhibitor) and trametinib (a selective inhibitor of MEK1/MEK2) were also demonstrated to improve survival among patients with metastatic melanoma [@bib0075; @bib0080].

The other operative treatment options include hepatic resection, hepatic intra-arterial chemotherapy, chemoembolization and hepatic perfusions [@bib0085].

Nowadays in literature there aren't randomized controlled studies to define the role of surgery in the treatment of hepatic metastases from melanoma.

In the era of the peri-operative chemotherapy and of the "target" therapy, the rules governing the treatment of the hepatic metastasis are changed. Therefore in the contest of improving surgical techniques, many surgeons have applied principles of hepatic metastasectomy to the treatment of other types of non-colorectal and non-neuroendocrine metastasis [@bib0015].

Although in colorectal cancer, it seems to be clear that hepatic resection is the only possibility of treatment associated with long-term survival and that all patients with resectable disease should be offered hepatic resection, these recommendations still need to be demonstrated for liver metastasis from melanoma. As reported by a recently systematic review, radical resection of liver metastases from melanoma appears to improve overall survival (OS) compared with non-operative management (22--66 months vs 4--12 months), but then, there is an high rate of tumor recurrences [@bib0015].

Three times as many, patients with ocular than cutaneous melanoma underwent resection for liver metastases, these differences can be found in a different radical resection rate and in a different recurrence site [@bib0015].

In literature there is the perception that liver metastases from ocular melanoma seem to be more frequently multiples and it is more difficult to obtain an R0 resection.

Many patients with ocular metastatic melanoma achieve only a R1-R2 resection after metastasectomy [@bib0015] and more likely recur within the liver, whereas patients with a cutaneous primary tumor more often develop extrahepatic involvement [@bib0090].

For the same reasons, the 5-year survival rate is also different with a worse prognosis for patients with liver metastases from cutaneous than ocular melanoma [@bib0090].

This distinctive behaviour is also sustained by a different metastatic latency to the liver. In ocular melanoma synchronous disease accounts for less than 1% of the cases [@bib0030], the majority of patients will develop liver metastasis during the subsequent follow-up period and some of these will present with metastatic ocular melanoma to the liver several years after the treatment of the primary tumor ([Table 1](#tbl0005){ref-type="table"}).

4. Conclusion {#sec0020}
=============

Currently, there is no consensus regarding the optimal follow-up, in terms of screening modality or time interval and there is no convincing evidence that surveillance improves overall survival.

On the other hand, seems to be essential to draw up a correct follow-up program after resection of ocular melanoma and after resection of subsequent liver metastasis to achieve optimal outcome. Therefore, patients with gastrointestinal symptoms and a history of choroidal melanoma should be investigated for the presence of gastrointestinal or liver metastases, although the original primary malignancy was diagnosed years before the patient's presentation.
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![Multiple liver metastases by choroidal melanoma.](gr1){#fig0005}

![A large mass involving the gallbladder and the anterior surface of the liver.](gr2){#fig0010}
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###### 

Cases of delayed presentation of metastatic choroidal melanoma to the liver.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Authors               Site        Age            Tumor size   Histology                         Treatment of primary tumor   DFI        Liver metastases                                             Treatment                       Liver recurrences                                                     Survival
  --------------------- ----------- -------------- ------------ --------------------------------- ---------------------------- ---------- ------------------------------------------------------------ ------------------------------- --------------------------------------------------------------------- ----------------------------------------------------------------------
  Gunduz [@bib0095]     Left eye    16 year-old\   10 × 8 mm    Mixed cell choroidal melanoma     Enucleation                  25 years   Multiple left liver metastases                               Left lobectomy                  After 4 years in the right lobe treated by wedge resection            DFS at 2 years
                                    Woman                                                                                                                                                                                                                                                                    

  Meda\                 Left eye    40 year-old\   8 × 4 mm     NS                                BRT with Cobalt 60           11 years   Single liver metastases                                      Metastasectomy + CHT            After 2 years in the right lobe treated by metastsectomy + RT + CHT   Dead after 5 years for: pulmonary, adrenal gland and bone metastases
  [@bib0100]                        Woman                                                                                                                                                                                                                                                                    

                        Left eye    50 year-old\   10 × 8 mm    Spindle cell choroidal melanoma   BRT with Cobalt 60           18 years   Single liver metastases                                      Metastasectomy + omentectomy    --                                                                    Alive at 2 years
                                    Man                                                                                                                                                                                                                                                                      

  Hosonuma [@bib0105]   Right eye   45 year-old\   NS           NS                                NS                           15 years   Multiple right liver metastasis                              CHT                             --                                                                    Dead after few months for hepatic failure
                                    NS                                                                                                                                                                                                                                                                       

  Orlando [@bib0110]    Right eye   42 year-old\   12 × 8 mm    Mixed cell choroidal melanoma     Enucleation                  7 years    Multiple liver metastasis                                    Explorative laparoscopy + CHT   --                                                                    Dead after 3 months for hepatic failure
                                    Woman                                                                                                                                                                                                                                                                    

  Our case              Right eye   60 year-old\   12 × 10 mm   Spindle cell choroidal melanoma   Enucleation                  20 years   Multiple liver metastasis + gallbladder and biliary system   None                            --                                                                    Dead after few months
                                    Man                                                                                                                                                                                                                                                                      
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

DFI: disease free interval; DFS: disease free survival; NBRT: brachiradiotherapy with Cobalt 60; RT: radiotherapy; CHT: systemic chemotherapy; S: non specified.
